Tech Company Financing Transactions

Igenica Funding Round

5AM Ventures, OrbiMed and The Column Group participated in a $14 million Series C funding round for Igenica. The round closed on 1/28/2014.

Transaction Overview

Company Name
Announced On
1/28/2014
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series C
Investors

5AM Ventures (John Diekman)

OrbiMed (Carl Gordon)

The Column Group (David Goeddel)

Third Rock Ventures (Mark Goldsmith)

Proceeds Purpose
As we strengthen our product focus, these funds will be used to advance IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia. It also will enable us to continue to discover and develop new therapeutics based on our innovative ADC platform to expand Igenica's pipeline and to increase strategic flexibility as we execute on our business and clinical development plans.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 102
Burlingame, CA 94010
USA
Email Address
Overview
Igenica is a biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.
Profile
Igenica LinkedIn Company Profile
Social Media
Igenica Company Twitter Account
Company News
Igenica News
Facebook
Igenica on Facebook
YouTube
Igenica on YouTube

Management Team

Title
Name
Email & Social
Chief Financial Officer
Hans van Houte
  Hans van Houte LinkedIn Profile  Hans van Houte Twitter Account  Hans van Houte News  Hans van Houte on Facebook
VP - Bus. Development
John Celebi
  John Celebi LinkedIn Profile  John Celebi Twitter Account  John Celebi News  John Celebi on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/28/2014: Madison Reed venture capital transaction
Next: 1/28/2014: Zinc venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary